FDA grants accelerated approval for Alzheimer’s Disease Treatment
The U.S. Food and Drug Administration approved Leqembi (lecanemab-irmb) via the accelerated approval pathway for the treatment of Alzheimer’s disease. Leqembi is the second of a new category of medications approved for Alzheimer’s disease that target the fundamental pathophysiology of the disease.